Ivonescimab before surgery for high-risk kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests giving the drug ivonescimab before surgery for patients with high-risk clear cell kidney cancer. The goal is to see if it can help shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of kidney cancer called clear cell renal cell carcinoma.
- Your cancer must be considered high-risk, such as a large or aggressive tumor that has not spread to other parts of the body.
- You need to be a candidate for surgery to remove all visible cancer from your kidney.
- You must be in good enough physical condition to have surgery and receive treatment, as measured by your daily activity level.
- Your kidney, liver, and blood cell counts must be within certain healthy ranges.
- You must not have received any prior cancer treatment for kidney cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving two immunotherapy drugs before surgery can safely shrink kidney cancer tumors and help your body fight the cancer. You would receive the drugs before your scheduled surgery, and then your cancer would be removed as planned.
This trial tests two combinations of investigational drugs for people with advanced clear cell kidney cancer that cannot be removed with surgery. The goal is to see if these combinations can shrink or control the cancer.
This trial tests a new drug, ivonescimab, for people with advanced clear cell kidney cancer that has grown after at least one prior treatment. It may help shrink tumors or slow the cancer's growth.
This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
This trial tests a combination of two drugs, cardenilimab and lenvatinib, given before and after surgery to remove kidney cancer. The goal is to see if this approach helps prevent the cancer from coming back. It is for people with early-stage (non-spread) clear cell kidney cancer who are healthy enough for surgery.
Hear when a new Stage II Renal Cell Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.